Home > Medical Devices >  In Vitro Diagnostics >  Treponema Pallidum Tests – In Vitro Diagnostics Tests Analysis and Forecast Model

Treponema Pallidum Tests – In Vitro Diagnostics Tests Analysis and Forecast Model

Incidence of Syphilis is increasing in most countries and geographical regions. This is predicted to lead to a higher number of suspected infection cases being tested as well as improved disease awareness and the implementation of new screening initiatives. However, disease incidence is not the only factor influencing the Treponema Pallidum or Syphilis Tests market. Sales of these devices are also heavily impacted by fluctuations in the number of pregnant women, semen donations, whole blood donations, and source plasma donations. While source plasma donations are expected to increase during the forecast period, live birth rates and voluntary whole blood donations are decreasing in many countries and this is expected to cause a decline in some North American, European, APAC, and Middle East and African markets. Additionally, Enzyme Immuno Assay (EIA) tests are predicted to be more frequently utilized in numerous countries. This switch in device usage is expected to bolster growth of the Syphilis Tests market overall, as EIA tests tend to be more expensive that some of their device counterparts.


This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Treponema Pallidum Test marketplace to make strategic planning and investment decisions.

• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Key Highlights

Competitive Assessment

Currently marketed Treponema Pallidum Tests and evolving competitive landscape:

• Insightful review of the key industry trends.

• Annualized total Treponema Pallidum Tests market revenue by segment and market outlooks from 2015–2028.

• Granular data on total procedures, units, average selling prices and market values by segment.

Reasons to Buy

The Treponema Pallidum Tests model will enable you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving Treponema Pallidum market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Treponema Pallidum market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.

• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

• Track device sales in the global and country-specific Treponema Pallidum market from 2015-2028.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned

• Becton Dickinson and Co

• Abbott Laboratories

• Siemens Healthcare GmbH

• Bio-Rad Laboratories Inc.

• Miraca Holdings Inc. (Fujirebio Inc.)

• Trinity Biotech Plc

• Arlington Scientific, Inc.

• Roche Diagnostics International Ltd

• Tecan Group Ltd (IBL International GmbH)

• Tulip Diagnostics (P) Ltd (Qualpro Diagnostics)

• Cardinal Health Inc.

• BioMerieux Inc.

• DiaSorin S.p.A.

• Omega Diagnostics Group Plc

• Rapid Labs Ltd

• Deben Diagnostics Ltd

• Lorne Laboratories Ltd

• Werfen Life Group SAU (Biokit S.A.)

• Sekisui Medical Co. Ltd.


Discounts available for multiple purchases.

+44 20 7947 2960

Join our mailing list

Saved reports